Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,257 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Local Disease Clear all

Conditions: Hypertension, Atherosclerosis
Interventions: Not listed
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 50 Years to 90 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Adenocarcinoma of the Prostate
Interventions: enzalutamide; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Cancer
Interventions: Saline, 0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 79 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pain, Postoperative, Anesthesia, Local, Opioid Use
Interventions: Bupivacaine, Dexmedetomidine, Placebo; Drug
Lead sponsor: Richmond University Medical Center; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 540 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Staten Island, New York

Conditions: Skin Ulcers, Sickle Cell Anemia
Interventions: Arginine Butyrate, Standard local care dressing; Drug · Other
Lead sponsor: Susan P. Perrine; Other
Eligibility: 16 Years to 60 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2005
U.S. locations: 4
States / cities: Chicago, Illinois • Boston, Massachusetts • New York, New York + 1 more

Conditions: Pain, Postoperative
Interventions: .5% bupivacaine with epinephrine; Drug
Lead sponsor: University of South Florida; Other
Eligibility: Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Cardiovascular Surgery, Pain, Postoperative, Block
Interventions: Liposomal bupivacaine, Normal Saline Flush, 0.9% Injectable Solution_#1; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Plano, Texas

Conditions: Childhood Langerhans Cell Histiocytosis, Fanconi Anemia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, melphalan, methylprednisolone, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: Up to 21 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Carpal Tunnel Syndrome
Interventions: MAC acupuncture needles, Electrostimulator 6c.Pro, Pantheon Research, Venice, CA; Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Anterior Cruciate Ligament Reconstruction, Regional Anesthesia, Saphenous Nerve Block
Interventions: Bupivacaine Only, Bupivacaine with 1 mg of Dexamethasone, Bupivacaine with 4 mg of Dexamethasone; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 16 Years to 65 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Local Anesthesia Injection Pain
Interventions: Local Anesthesia (lidocaine hydrochloride), Iontophoresis of Tetracaine and oxymetazoline; Drug
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Peripheral Vascular Disease
Interventions: External Electric Muscle Stimulation; Device
Lead sponsor: Rosenblum, Jonathan I., DPM; Individual
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Inguinal Hernia, Anesthesia, Local
Interventions: Open Inguinal Hernia Repair - Local Anesthesia, Inguinal Hernia Repair - General Anesthesia; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 60 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Dallas, Texas • Houston, Texas • Madison, Wisconsin

Conditions: Postoperative Pain
Interventions: Bupivicaine Infusion; Drug
Lead sponsor: Chang, Steve S., M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Bowel Disease
Interventions: Liposomal Bupivicaine/Bupivacaine Admixture, Bupivacaine HCL; Drug
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Safety of Neosaxitoxin in Healthy Volunteers
Interventions: Neosaxitoxin in saline, NeoSTX + bupivacaine 0.2%, NeoSTX + bupivacaine 0.2% + epinephrine 5mcg/ml, Saline placebo; Drug · Other
Lead sponsor: Charles Berde; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Complex Regional Pain Syndromes
Interventions: 80mg/day Ketamine HCl Prolonged Release, 160mg/day Ketamine HCl Prolonged Release; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 64 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypospadias, Penile Torsion, Chordee, Phimosis
Interventions: Caudal Block, Ultrasound-guided Pudendal Block, Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine, Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine.; Procedure · Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 6 Months to 3 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: HIV Infections
Interventions: UC-781, UC-781 placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
Interventions: PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease, Goserelin, Histrelin, Leuprolide & Triptorelin, ADT + Nilutamide, Flutamide, & Bicalutamide, Degarelix & Relugolix, ADT + Docetaxel +/- prednisone, ADT + Abiraterone + Prednisone, ADT + Abiraterone + Methylprednisolone, ADT + Apalutamide, ADT + Enzalutamide, Prostate-directed Radiation for De novo oligometastatic prostate cancer; Procedure · Radiation · Other + 1 more
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 20
States / cities: Long Beach, California • West Los Angeles, California • Washington D.C., District of Columbia + 17 more

Conditions: HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm, Primary Liver Cancer, Liver Neoplasm
Interventions: Lumason, Sonazoid; Diagnostic Test
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Head and Neck Cancer
Interventions: Cetuximab, Cisplatin, Nab-Paclitaxel, intensity-modulated radiation therapy; Biological · Drug · Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Healthy Volunteers
Interventions: EXPAREL; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Bladder Cancer, Kidney Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions: immunologic technique, laboratory biomarker analysis, mass spectrometry; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Search by objective public record fields.

Age-Related Changes in Body Composition

Enzalutamide in Patients With High-risk Prostate Cancer

Selective Intraoperative Administration of Local Anesthesia in Breast Reconstruction

Wound Infiltration as Part of an Opioid Free Pain Management Pathway Following Cesarean Delivery

Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers

Cesarean Delivery and Post-operative Pain Management With Local Anesthesia

Sternal Block With Liposomal Bupivacaine vs. Saline Prior to Incision in Cardiac Surgery

Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases

Local Effects of Acupuncture and Nerve Conduction Studies

Comparing Subsartorial Saphenous Nerve Blocks With and Without Dexamethasone for Anterior Cruciate Ligament Reconstruction

Clinical Evaluation of no Needle Dental Anesthesia Compared to Syringe Anesthesia Delivery

Evaluation of the Effect of the Flowaid Device in Increasing Local Circulation in the Leg

A Pilot Study of Local Anesthesia for Inguinal Hernia Surgery in Older Adults

Bupivicaine to Reduce Postoperative Pain in Laparoscopic Ventral Hernia Repair

Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy

Safety Study of Long-Acting Local Anesthetic

Ketamine HCl Prolonged Release Oral Tablets for CRPS

Caudal vs. Pudendal Block in Peds GU

Phase I Study of Safety and Persistence of UC-781 Vaginal Microbicide

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

Y-90 Treatment Response Using Transarterial Radioembolization

Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer

Safety and Pharmacokinetics Study of Redosing EXPAREL in Healthy Volunteers

Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants